September 12, 2022 + Jessica Di Palo
2 Minuten zu lesen
Real Deals has compiled a list of the most influential individuals, firms and movements that have defined, innovated and transformed private equity over the last twelve months.
We are happy to share the news that Dr. Christoph Kausch, our Managing Partner at MTIP, made the list for Real Deals most influential for 2022. Real Deals publishes the most important European private equity news, alongside deep analysis and comprehensive deal coverage.
MTIP marks its place on this year’s list for being one of the first investors active in the healthtech space. Founding member of the Swiss-based growth equity healthtech investor, Dr. Christoph Kausch, has been instrumental in tailoring the firm’s investment thesis, backing digital health and digitally connected medical device companies. MTIP also takes an active role in ESG, with its second fund achieving “dark green” status as an Article 9 fund within SFDR. The practicalities of achieving Article 9 status have really come to light in 2022, with many of the latest PE fundraisings only able to get as high as Article 8. The status was achieved for MTIP’s contribution to tackling “inequality in access to quality healthcare for disadvantaged communities”. The GP also has a significant focus on social responsibility.
“Our mission at MTIP is to build the healthtech leaders of tomorrow,” said Dr. Christoph Kausch, Managing Partner at MTIP. “The trust our investors have put in us is a great endorsement of our strategy that’s built on our sector focus and proven approach to value creation. Being listed as one of Real Deals most influential individuals of 2022 is a phenomenal recognition for the achievements we secured in the last 12 months.”
MTIP is a leading Swiss-based growth equity firm investing in European healthtech companies. We leverage our deep sector expertise to help the founders scale up successful and sustainable digital health businesses. At MTIP, we are driven by the mission to empower healthtech innovation with the potential to impact and improve millions of lives.
Christoph Kausch selected by Real Deals as most influential for 2022
Christoph Kausch named by Real Deals most influential for 2022
MTIP leads €17 million financing round in virtual fertility clinic Apricity
New MTIP investment
MTIP leads the €20 million growth financing round in LynxCare
Largest capital round ever in digital health in Belgium
Pioneering the use of machine learning algorithms to turbo-charge drug development
Intelligencia revolutionizes drug development
The psychology of decision making
What makes a good investor?
MTIP schliesst zweiten Healthtech Growth Fonds mit $250 Millionen
MTIP schliesst zweiten Healthtech Fund
Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics
Cynerio's new product Cynerio Now!
MTIP invests in Mediktor
Dieser Text erscheint auf allen Übersichtsseiten (z.B. Story-Karussell)
MTIP invests in Mediktor
MTIP investiert in medizinischen Assistenten
SFDR Art. 8 or Art. 9? What’s the difference?
SFDR: getting the terminology right
MTIP participates in Oviva’s new $80m Series C funding
MTIP invests in Oviva
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
MTIP's new investment in Intelligencia
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round